Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 sept. 2019 02h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade

NANTES, France, Sept. 30, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) presented new data on its BiCKI® platform at the International Cancer Immunotherapy...
18 sept. 2019 12h15 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063

First-in-Class Myeloid Checkpoint Inhibitor BI 765063* is Currently in Phase 1 Clinical Development in Advanced Solid Tumors in Partnership with Boehringer IngelheimMilestone Endorses OSE’s Business...
05 sept. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update

Major clinical progress with four differentiated therapeutic programs in immuno-oncology and autoimmune diseases;Received €25 M in milestones from collaborations with Servier and Boehringer...
03 sept. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients

NANTES, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) today announces the grant of a new patent from the European Patent Office (EPO)...
23 juil. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives a Grant from the French National Research Agency to Validate New Targets Linked to Myeloid Cells And Identify Innovative New Immunotherapies in Oncology

Research program coordinated by the Cancer Research Center of Lyon within the Léon Bérard Cancer Center NANTES, France, July 23, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173;...
17 juil. 2019 01h00 HE | Source: OSE Immunotherapeutics

First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation

Findings show the role of the SIRPα/CD47 axis in the maintenance of acquired immune toleranceHighlights the differentiated mechanism of action of OSE's innovative myeloid checkpoint inhibitor BI...
10 juil. 2019 12h07 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives Special Recognition for European Growth, Healthcare Enterprise and Women Entrepreneurship

NANTES, France, July 10, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announces that it received special recognition for European growth, healthcare enterprise...
26 juin 2019 12h30 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

NANTES, France, June 26, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General...
24 juin 2019 01h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)

NANTES, France, June 24, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) will participate in the first HealthTech Investor Days business event, hosted by France...
20 juin 2019 12h00 HE | Source: OSE Immunotherapeutics

Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation

NANTES, France, June 20, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that, after reviewing global study data, the Independent Data Monitoring...

Page précédente